Last reviewed · How we verify
Xenaderm
Xenaderm is a Small molecule drug developed by Healthpoint. It is currently in Phase 2 development. Also known as: Placebo Comparator.
Xenaderm Ointment is a treatment option studied for various conditions, including pressure ulcers, spinal cord injury, and wounds. It has been compared to standard care in clinical trials for managing stage I-II pressure ulcers in individuals with spinal cord injury.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Xenaderm |
|---|---|
| Also known as | Placebo Comparator |
| Sponsor | Healthpoint |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Treatment of Anterior Blepharitis With Microblepharoexfoliation Procedure (NA)
- Comparison of HP011-101 to Standard Care for Stage I-II Pressure Ulcers in Subjects With Spinal Cord Injury (PHASE2)
- Clinical Evaluation of the Phototoxic Potential of Xenaderm Ointment (PHASE1)
- Controlled Study of the Effect of Xenaderm® Ointment Vehicle Versus White Petrolatum on Healing (PHASE2)
- Feasibility Study of the Execution of an Efficacy Trial in the Nursing Home Setting (PHASE2)
- Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xenaderm CI brief — competitive landscape report
- Xenaderm updates RSS · CI watch RSS
- Healthpoint portfolio CI
Frequently asked questions about Xenaderm
What is Xenaderm?
Who makes Xenaderm?
Is Xenaderm also known as anything else?
What development phase is Xenaderm in?
Related
- Manufacturer: Healthpoint — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Placebo Comparator
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing